North Bay Business Journal

BioMarin acquires ZyStor in $115 million deal

NOVATO — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today said it acquired privately held biotechnology company ZyStor Therapeutics Inc. in a deal valued at $115 million.

Benicia exploring ways to attract technology companies

BENICIA — As a means of attracting more jobs to the city, Benicia is considering adjusting zoning and land-use laws that would permit more tech and development companies to occupy about one third of the city’s land area, including all of its industrial park.

TriVascular obtains new $60 million infusion

SANTA ROSA — TriVascular of Santa Rosa, California, announced today the close of $60 million in funding, comprised of a Series C equity financing and growth capital venture debt.

TriVascular in first U.S. clinical trial; will add 100 jobs

SANTA ROSA — TriVascular announced today the first U.S. clinical study of its abdominal stent graft, a device that promises to significantly increase the pool of candidates for minimally invasive treatment of aortic aneurisms.

BioMarin launches drug in Europe

NOVATO — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Firdapse is now commercially available in Germany and the UK.

For the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome, Firdapse is expected to be in all major European markets by the end of 2010.

TriVascular trials progress in Europe

SANTA ROSA — TriVascular’s abdominal stent graft is showing solid results in European clinical trials, well on its way to holding a leading position in a predicted $2 billion global market.

BioMarin acquires LEAD Therapeutics

NOVATO — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said it plans to acquire LEAD Therapeutics Inc. of San Bruno in a stock deal worth $18 million up front and up to $97 million as the drug is submitted for government review and later released.

TriVascular gets $30 million Series B

SANTA ROSA –TriVascular Inc. announced today it has raised $30 million in a Series B offering. The funds will take the maker of abdominal and thoracic stent graft systems into clinical testing.

The Series B financing is a continuation of Series A funding of $65 million in 2008 from investors New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.

BioMarin acquires Huxley Pharmaceuticals

NOVATO — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has acquired Huxley Pharmaceuticals inc. for $15 million, with further payments to Huxley shareholders of up to $50 million if certain milestones are reached.

BioMarin, doubling manufacturing capacity, sees quarterly earnings decline

NOVATO — BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) said today investments made to double manufacturing capacity caused it to post lower second-quarter profit as operating expenses jumped 32 percent during the quarter.